



2026-27 APPLICATION

Preparation worksheet for the 2026-27 edition (2nd edition call)

This worksheet mirrors the official online application form so you can prepare your answers in advance, with your team, before entering them into the Google Form. **It does not replace the form** — it's a working document to help you draft, review, and align internally on your responses first.

Applications must be submitted exclusively through the official form [at this link](#) in English before 11:59pm Pacific Time (PT) on 27 September 2026 — or 8:59am Central European Summer Time (CEST) on 28 September 2026.

Please review the [full terms and conditions](#) of the call before starting.

BEFORE YOU START: ELIGIBILITY CHECK

Please confirm that all of the following statements are true for your project. If any of them are not, your project will not be admitted to the evaluation phase — so it's worth checking all of them before investing time in the rest of the application.

- ✓ *Our project addresses needs in fetal, neonatal, pediatric, and/or maternal health.*
- ✓ *Our solution is a medical device (including diagnostics), a digital health solution, or a healthcare service.*
- ✓ *Our project is at least at proof-of-concept stage (TRL 3) and at most at the stage where the technology has been demonstrated in a relevant environment (TRL 6).*
- ✓ *Our project/company is based in the US and/or EU.*
- ✓ *We are interested in entering the opposite market (US or EU) to the one we're based in.*
- ✓ *Our team has at least one member with full-time dedication.*
- ✓ *Our team can commit at least 80% of total team dedication to participating fully in the program's activities.*
- ✓ *Our project has raised less than \$5 million USD in total **dilutive** funding to date.*

Section 1 — Contact and General Information

- Primary contact name
(Up to 100 characters)
- Primary contact e-mail
(Up to 100 characters)
- Primary contact LinkedIn profile (optional)
(Up to 100 characters)
- Project or company name
(Up to 100 characters)
- Project or company website (optional)
(Up to 100 characters)
- Project or company LinkedIn profile (optional)
(Up to 100 characters)
- Project or company primary location (City, Country):
Where the team or company is legally based or primarily operating from *(Up to 100 characters)*
- Date project or company was founded
(Up to 100 characters)
- Is the company incorporated?:
Yes / No
- Project or company stage (Technology Readiness Level, TRL 1–9)
Choose the level that best reflects where the project stands today — from an identified need (TRL 1) through clinical use (TRL 9). Remember eligible range is TRL 3–6.¹

Section 2 — Need and Technology

- Target disease/condition and incidence
Name the specific condition you address and share incidence/prevalence data if available. (Up to 3000 characters).
- Primary target patient population
Fetal / Neonatal / Pediatric / Maternal / Other
- Description of the unmet need and current standard of care.
What is missing today, and how is this need currently addressed (or not)? (Up to 2000 characters).

¹ For an illustrated overview of the Technology Readiness Level (TRL) scale, see: Dr. Zhong Wei (Derrick) Khor, "Technology Readiness Levels: A Quick Guide to Understanding TRLs in the NHS HealthTech Context," infographic produced by Medical Consulting Group, published on LinkedIn, accessed July 2026, https://www.linkedin.com/posts/derrick-khor_today-we-are-learning-an-important-healthtech-activity-7381236927372480512-2vkgq

- Proposed solution — write a concept summary.
A clear, concise description of what your solution is and how it works. (Up to 2000 characters).
- Proposed solution — type of solution
(Medical device / Digital health / Diagnostics / Service / Other)
- Value proposition for different stakeholders and anticipated impact of the solution. *(Up to 2000 characters).*
Consider patients, families, clinicians, health systems, and payers — what does each gain? (Up to 2000 characters).
- Market size
(Up to 2000 characters).
- Competition and differentiation.
Who else addresses this need, and what makes your approach different or better?. (Up to 2000 characters).
- IP strategy and status
(Up to 2000 characters).
- Validation strategy (preclinical testing and clinical trials) and status
(Up to 2000 characters)
- Regulatory strategy and status.
(Up to 2000 characters).
- Business model, reimbursement and pricing strategy.
(Up to 2000 characters).
- Go-to-market expected date
(Up to 200 characters).

Section 3 — Team, Funding, and Support Required

- Team members.
For each member: name, role, dedication (%FTE), professional background, and years of relevant experience. (Up to 2000 characters).
- Previous team experience in developing or commercializing solutions.
If applicable, note whether this experience includes pediatric and/or maternal health, and the type of solution involved (medical device, digital health, healthcare service, etc.). (Up to 2000 characters).
- Previous team exits (if any) — please describe.
(Up to 2000 characters).

- Funding: amount and sources of non-dilutive and dilutive funding raised to date.
(Up to 1000 characters).
- Support required.

Describe your development plan and how the program's support over the next 6 months could help you reach key milestones. (Up to 2000 characters).

CONTACT INFORMATION

For questions or more information, please contact:

- Antje Kirschner, Chief of Staff – Impact1 at Stanford Biodesign.
akirschner@stanford.edu
- Sofia Ferreira Quartino, Internal Innovation Manager – i4KIDS at SJD Barcelona Children's Hospital sofia.ferreira@sjd.es